Skip header and navigation

10 records – page 1 of 1.

Document Type
Evidence Search Report
Review Code
PPE030101-01 ESR
Question Submitted
March 1, 2021
Date Completed
March 3, 2021
Status
6. Cancelled
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE030101-01 ESR
Question Submitted
March 1, 2021
Date Completed
March 3, 2021
Status
6. Cancelled
Research Team
Personal Protective Equipment
Notes
Work was not completed before the project was no longer supported
Category
Administration
Infection Prevention and Control
Subject
Transmission
Personal Protective Equipment
Priority Level
Level 2 One week (7 days)
Cite As
Dalidowicz, M; Fox, L. What is the risk of COVID-19 acquisition via exposures of the ocular mucosa? 2021 Mar 3; Document no.: PPE030101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 51 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
PPE120901 RR
Question Submitted
December 9, 2020
Date Completed
December 18, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Rapid Review
Review Code
PPE120901 RR
Question Submitted
December 9, 2020
Date Completed
December 18, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Key Findings
Moderate evidence supporting the concept that airway management and certain surgical procedures create aerosols
No definitive evidence for the transmission of SARS-CoV-2 during AGMP
Indirect evidence from SARS-CoV-1 indicates that HCW present during AGMP are at higher risk of infection, but evidence quality is very low and very difficult to generalize
The absence of definitive evidence does not equate to the absence of risk and most policy recommendations err on the side of safety for Health Care Workers
Category
Infection Prevention and Control
Subject
Aerosols
Risk
Transmission
Population
All
Clinical Setting
Ambulatory
Long Term Care
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Groot, G; Fox, L; Mueller, M. What is the risk of COVID-19 transmission during AGMP procedures? 2020 Dec 18; Document no.: PPE120901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PPE120901-01 ESR
Question Submitted
December 9, 2020
Date Completed
December 11, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE120901-01 ESR
Question Submitted
December 9, 2020
Date Completed
December 11, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Category
Infection Prevention and Control
Subject
Aerosols
Risk
Transmission
Population
All
Clinical Setting
Ambulatory
Long Term Care
Priority Level
Level 2 One week (7 days)
Cite As
Fox, L; Mueller, M. What is the risk of COVID-19 transmission during AGMP procedures? 2020 Dec 11; Document no.: PPE120901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 41p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
PPE110203 RR
Question Submitted
November 2, 2020
Date Completed
November 20, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Rapid Review
Review Code
PPE110203 RR
Question Submitted
November 2, 2020
Date Completed
November 20, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Key Findings
Laboratory testing of expired masks maintain an acceptable filtration performance with less than 2% failing testing in a study of nearly 4,000 masks from 93 lots
Another study assessing stockpiled N95 masks in Taiwan found acceptable filtration up to 13 years post storage
Guidelines indicate that expired N95 respirators should be used before resorting to extended use/reuse
Category
Infection Prevention and Control
Subject
Face Masks
Health Personnel
Population
All
Priority Level
Level 3 Two weeks (14 days)
Cite As
Badea, A; Groot, G; Dalidowicz, M; Miller, L. What evidence is available regarding degradation of N95 respirators/masks? 2020 Nov 20; Document no.: PPE110203 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
PPE110201 RR
Question Submitted
November 2, 2020
Date Completed
November 20, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Rapid Review
Review Code
PPE110201 RR
Question Submitted
November 2, 2020
Date Completed
November 20, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Key Findings
N95 respirators that have been reprocessed demonstrate acceptable fit and filtration performance under laboratory conditions
Increased use over time both in terms of length of wear and number of donning/doffings increases the likelihood of fit failure
Reprocessing masks does not render them to ‘new’ condition
Category
Infection Prevention and Control
Subject
Face Masks
Health Personnel
Population
Other
Clinical Setting
Other
all clinical (and non) settings
Priority Level
Level 4 Three weeks (21 days)
Cite As
Badea, A; Groot, G; Dalidowicz, M; Miller, L. What is the evidence to support the reprocessing and re-use of N95 respirators by healthcare workers? 2020 Nov 20; Document no.: PPE110201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 19 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PPE110203-01 ESR
Question Submitted
November 2, 2020
Date Completed
November 10, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE110203-01 ESR
Question Submitted
November 2, 2020
Date Completed
November 10, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Category
Infection Prevention and Control
Subject
Face Masks
Health Personnel
Population
All
Priority Level
Level 3 Two weeks (14 days)
Cite As
Dalidowicz, M; Miller, L. What evidence is available regarding degradation of N95 respirators/masks? 2020 Nov 10; Document no.: PPE110203-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 16 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PPE110201-01 ESR
Question Submitted
November 2, 2020
Date Completed
November 6, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE110201-01 ESR
Question Submitted
November 2, 2020
Date Completed
November 6, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Category
Infection Prevention and Control
Subject
Face Masks
Health Personnel
Population
Other
Clinical Setting
Other
all clinical (and non) settings
Priority Level
Level 4 Three weeks (21 days)
Cite As
Dalidowicz, M; Miller, L. What is the evidence to support the reprocessing and re-use of N95 respirators by healthcare workers? 2020 Nov 6; Document no.: PPE110201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 28 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
PPE041701 RR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Rapid Review
Review Code
PPE041701 RR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Key Findings
The most commonly reported symptoms inCOVID-19patientswere: fever (79-89%); cough (58-69%); fatigue/muscle aches (29-36%); dyspnea (22-38%); chest distress (31%); and expectoration (12-29%).
Less common were various GI symptoms (9-18%) including diarrhea (5-7%) and nausea (4%),as well as sore throat (10-12%) and headache (6-12%).
Although the Government of Canada lists runny nose as a potential symptom for a suspect case, it was not reported as such in the meta-analyses examined.
Category
Clinical Presentation
Subject
Natural History
Symptoms
Screening
Priority Level
Level 2 completed within 8 hours
Cite As
McCarron, M; Groot, G; Dalidowicz, M; Miller, L. What distinguishes COVID-19 from influenza-like illnesses? 2020 Apr 17; Document no.: PPE041701 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PPE041701-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE041701-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Category
Clinical Presentation
Subject
Natural History
Symptoms
Screening
Priority Level
Level 2 completed within 8 hours
Cite As
Miller, L; Dalidowicz, M. What distinguishes COVID-19 from influenza-like illnesses? 2020 Apr 16; Document no.: PPE041701-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PPE041702-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE041702-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Notes
This was never assigned to an RR
Category
Clinical Management
Infection Prevention and Control
Subject
Aerosols
Personal Protective Equipment
Decision Making
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Miller, L; Dalidowicz, M. What is the clinical evidence used to support aerosol generating medical procedures recommendations and guidelines regarding line flow volume or pressure? 2020 Apr 11; Document no.: PPE041702-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report)
Related Documents
Documents
Less detail

10 records – page 1 of 1.